Blog of Signaling Pathways

Inhibitory Response to CK II Inhibitor Silmitasertib and CDKs Inhibitor Dinaciclib Is Related to Genetic Differences in Pancreatic Ductal Adenocarcinoma Cell Lines

74 views | Jun 09 2022

Yixuan Ma et al. thought that specific aberrations in TP53 and KRAS affected the efficacy of both inhibitors. [Read the Full Post]

In vitro modeling of liver fibrosis in 3D microtissues using scalable micropatterning system

64 views | Jun 08 2022

Ensieh Zahmatkesh et al. found that aHSCs could lead to EMT in hepatocytes during liver fibrogenesis. [Read the Full Post]

Insights into Immune Escape During Tumor Evolution and Response to Immunotherapy Using a Rat Model of Breast Cancer

78 views | Jun 08 2022

Carlos R Gil Del Alcazar et al. demonstrated the usefulness of this preclinical model for immunotherapy and suggested examination to expand immunotherapy to a subset of patients with ER+ disease. [Read the Full Post]

Lonafarnib Inhibits Farnesyltransferase via Suppressing ERK Signaling Pathway to Prevent Osteoclastogenesis in Titanium Particle-Induced Osteolysis

126 views | Jun 07 2022

Linke Huang et al. found that Lon was a promising treatment option for osteoclast-related osteolysis diseases including periprosthetic osteolysis by targeted inhibition of FTase through suppressing ERK signaling. [Read the Full Post]

RNF43 R117fs mutant positively regulates Wnt/β-catenin signaling by failing to internalize FZD expressed on the cell surface

61 views | Jun 07 2022

A-Ri Cho et al. demonstrated that RNF43 frameshift mutations retained normal functionality; thus, targeted anti-cancer therapy could be developed according to the mutation type of RNF43. [Read the Full Post]

Acid-Responsive Micelles Releasing Cinnamaldehyde Enhance RSL3-Induced Ferroptosis in Tumor Cells

84 views | Jun 06 2022

Ziliang Yan et al. confirmed that RSL3@PCA has excellent inhibition of tumor growth without significant toxicity to normal cells and tissues and still has a good therapeutic effect on tumor cells that are resistant to conventional chemotherapy drugs. [Read the Full Post]

Membrane Attack Complex C5b-9 Promotes Renal Tubular Epithelial Cell Pyroptosis in Trichloroethylene-Sensitized Mice

38 views | Jun 06 2022

Feng Wang et al. found that complement C5b-9 played a central role in TCE-induced immune kidney damage, and the underlying mechanisms involved NLRP3-mediated pyroptosis. [Read the Full Post]

Impact of Smoking on Response to the First-Line Treatment of Advanced ALK-Positive Non-Small Cell Lung Cancer: A Bayesian Network Meta-Analysis

90 views | Jun 05 2022

Kehai Lin et al. thought that lorlatinib in never-smokers and low-dose alectinib in smokers could be considered optimal first-line therapy for advanced ALK-positive NSCLC. [Read the Full Post]

Congenital sideroblastic anemia model due to ALAS2 mutation is susceptible to ferroptosis

76 views | Jun 05 2022

Koya Ono et al. found that defective heme biosynthesis in XLSA clones could confer enhanced BACH1 expression, leading to increased susceptibility to ferroptosis. [Read the Full Post]

A Combination of Cytokine-Induced Killer Cells With PD-1 Blockade and ALK Inhibitor Showed Substantial Intrinsic Variability Across Non-Small Cell Lung Cancer Cell Lines

88 views | Jun 03 2022

Yutao Li et al. supported the idea that combination therapies offer significant potential when they are optimized on a patient-by-patient basis. [Read the Full Post]

Three Birds, One Excipient: Development of an Improved pH, Isotonic, and Buffered Ketamine Formulation for Subcutaneous Injection

97 views | Jun 03 2022

Jason Wallach et al. found that this strategy has the potential to be readily adapted to other amine-based APIs. [Read the Full Post]

Stability of Captisol-enabled versus propylene glycol-based melphalan at room temperature and after refrigeration

94 views | Jun 03 2022

Jitesh D Kawedia et al. found that CE-melphalan at 2 mg/mL has 24-hour stability at RT and can be used for extended infusion times or may be compounded ahead of time. Reconstituted CE-melphalan vials are stable for 48 hours at both RT and 4 °C. [Read the Full Post]

Complete and durable response to crizotinib in a patient with malignant pleural mesothelioma harboring CD74-ROS1 fusion

108 views | Jun 02 2022

Xuehua Xie et al. described a case of MPM with CD74-ROS1 fusion who obtained complete and durable response after receiving crizotinib. [Read the Full Post]

Dihydroquercetin Attenuates Silica-Induced Pulmonary Fibrosis by Inhibiting Ferroptosis Signaling Pathway

90 views | Jun 02 2022

Leyong Yuan et al. found that inhibition of ferritinophagy-mediated HBE cells ferroptosis was responsible for DHQ to ameliorate SiO2-induced lung fibrosis, which provided a preliminary theoretical basis for the clinical application of DHQ in the treatment of silicosis. [Read the Full Post]

Human primary liver cancer-derived organoid cultures for disease modeling and drug screening

0 views | Jun 01 2022

Laura Broutier et al. demonstrated the wide-ranging biomedical utilities of PLC-derived organoid models in furthering the understanding of liver cancer biology and in developing personalized-medicine approaches for the disease. [Read the Full Post]

Physicochemical Characterization, Molecular Docking, and In Vitro Dissolution of Glimepiride-Captisol Inclusion Complexes

90 views | Jun 01 2022

Arpita Pal et al. found that complexation with Captisol enhanced the water solubility of glimepiride. [Read the Full Post]


119 views | May 31 2022

Pedro M Rodrigues et al. suggested that LAMP2 interconnected the autophagy-lysosomal axis and the processing of selecting self-peptides:MHC II complexes in cTECs, underling its implications for the generation of a broad CD4 TCR repertoire. [Read the Full Post]

SK119, a Novel Shikonin Derivative, Leads to Apoptosis in Melanoma Cell Lines and Exhibits Synergistic Effects with Vemurafenib and Cobimetinib

54 views | May 31 2022

Nadine Kretschmer et al. thought that SK119 treatment changed the expression levels of apoptosis genes and death receptor expression and exhibited synergistic effects with vemurafenib and cobimetinib in human melanoma cells. [Read the Full Post]

Combined Treatment with PI3K Inhibitors BYL-719 and CAL-101 Is a Promising Antiproliferative Strategy in Human Rhabdomyosarcoma Cells

60 views | May 30 2022

Manuela Piazzi et al. indicated that BYL-719, either alone or in combination with the p110δ inhibitor, CAL-101, could represent an efficient treatment for human rhabdomyosarcoma presenting with aberrant upregulation of the PI3K signaling pathway. [Read the Full Post]

The role of autophagy in cadmium-induced acute toxicity in glomerular mesangial cells and tracking polyubiquitination of cytoplasmic p53 as a biomarker

134 views | May 30 2022

Ki-Tae Jung et al. indicated that cytoplasmic polyUb-p53 was a potential biomarker for Cd-induced acute toxicity in mesangial cells. [Read the Full Post]